Groundbreaking Study Results
An international multicenter analysis has revealed remarkable outcomes for patients receiving CyberKnife radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) for brainstem metastases. The study, published in the International Journal of Cancer, demonstrates impressive long-term benefits and safety profiles despite treating highly sensitive brain regions.
Revolutionary Treatment Approach
Dr. Felix Ehret from Charité – Universitätsmedizin Berlin emphasizes the critical nature of brainstem metastases treatment. The study showcases how CyberKnife’s precision technology offers hope where traditional surgery isn’t viable, positioning radiosurgery as a cornerstone treatment option.
Advanced Technology Benefits
The CyberKnife System delivers radiation with sub-millimeter accuracy in just one to five sessions. Unlike traditional methods, patients avoid metal frame head attachments, making treatment accessible to a broader patient population, including those with recurrent tumors and younger patients.
Impressive Clinical Outcomes
The comprehensive study analyzed 136 patients across nine institutions from 2005 to 2022. Results showed remarkable local control rates:
- 82.9% at one year
- 71.4% at two years
- 61.2% at three years
Treatment Flexibility and Safety
CyberKnife offers versatile treatment options, serving as both primary and adjuvant therapy. The study confirmed excellent tolerability with minimal side effects, despite treating delicate brain areas. This breakthrough technology represents a significant advancement in brain tumor treatment, offering hope to patients worldwide.
Leave a Reply